A study on the correlation between serum levels of fibroblast growth factor-19 and cardiovascular risk factors in patients with metabolic syndrome

Metabolic syndrome is a major global threat nowadays due to urbanization, sedentary life style and increased incidence of obesity. FGF-19 has recently been introduced as a novel marker regulating metabolism, reversing diabetes mellitus, hyper lipidemia, hepatic steatosis and adiposity. Aim & Objective: To compare the serum Fibroblast Growth Factor 19 levels of metabolic syndrome patients with healthy individuals. To analyze the correlation between serum FGF 19 and the components of metabolic syndrome. Materials & Methods: A total of 50 patients and 50 controls were included in the study. After obtaining informed consent, anthropometric measures (Height, Weight, BMI & Waist circumference) were taken. Blood investigations such as FGF 19, TC, HDL-cholesterol were estimated and LDL, VLDL & AIP levels were calculated. Statistical Analysis: Student’s t-test was employed for the statistical analysis and data were expressed in terms of mean and standard deviation. ‘p’ value less than 0.05 is considered as statistically significant. Correlation between the measured parameters was assessed using Pearson’s correlation coefficient. Result & Conclusion: Serum levels of FGF 19 were low in patients with metabolic syndrome.